Scientific exchange · Dr. Liam Quinn

14 Jan 2026 · Phone · Dr. Liam Quinn, Institut Curie · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0144—

Capture insight from this engagement

Location: Institut Curie
Therapeutic area: Nephrology
Country: France
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

Patient-reported outcomes
Proteinuria as surrogate endpoint
APRIL pathway mechanism

Scientific content used

APRIL-IgAN Phase III topline

Questions raised

Is there any data on APRIL inhibition in FSGS?

Notes

Scientific exchange with academic nephrologist at Institut Curie. Discussed patient-reported outcomes, proteinuria as surrogate endpoint, april pathway mechanism.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 2
Depth of exchange: 5
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0144

Audit history (0)

All create, update and approval events for this record

No audit events in sample data